Previous close | 5.48 |
Open | 5.42 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.42 - 5.42 |
52-week range | 4.22 - 8.90 |
Volume | |
Avg. volume | 7,179 |
Market cap | 62.083M |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.62 |
Earnings date | 22 May 2024 - 27 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.00 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on April 4th at 10:00 am Eastern Daylight Time.